酶激活式抗肿瘤前体药物的研究进展
作者：张田甜;刘鹏;杜军;蔡绍晖;
Author：
收稿日期： 年卷（期）页码：2007,(05):-536-538
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：前列腺特异性抗原;基质金属蛋白酶;成纤维细胞激活蛋白;抗癌前体药物
Key words：
基金项目：国家自然科学基金资助项目(批准号:30471978);;
广东省自然基金资助课题(批准号:5001771)
中文摘要
酶激活式抗肿瘤前体药物利用特异表达于肿瘤组织的酶激活本无活性的前体药物而发挥靶向肿瘤细胞的细胞毒作用。本文根据肿瘤组织自身表达酶的部位、种类、结构、功能和性质的不同,阐述了现有几种酶激活式前体药物的工作原理和研究现状,比较了该类前药与人工引入酶激活式前药的优劣,评价其发展前景。
参考文献
[1]Hyo-Kyung Han,Gordon L Amidon.Targeted Prodrug Designto Optimize Drug Delivery[J].AAPS Pharmsci,2000,2(1):1-11.
[2]Guang Xu,Howard L McLeod.Strategies for Enzyme/ProdrugCancer Therapy[J].Clinical Cancer Research,2001,7:3314?3324.
[3]Deborah DeFeo-Jones,Stephen F Brady,Dong-Mei Feng,etal.A Prostate-specific Antigen(PSA)-activated VinblastineProdrug Selectively Kills PSA-secreting Cellsin vivo[J].Molec-ular Cancer Therapeutics,2002,1:451?459.
[4]Deborah Defeo-jones,Victor m Garsky.Apeptide?doxorubi-cin‘prodrug’activated by prostate specific antigen selectivelykills prostate tumor cells positive for prostate-specific antigen invivo[J].Nature Medcine,2000,6(11):1248-1252.
[5]Samuel R Denmeade,Carsten M Jakobsen,Samuel J,et al.Prostate-specific antigen-activated thapsigargin prodrug as tar-geted therapy for prostate cancer[J].Nat Can Insti,2003,95(13):990-1000.
[6]李斌.PSA激活的前体药物疗法治疗前列腺癌研究进展[J].中国肿瘤生物治疗杂志,2004,11(2):154-156.
[7]Robert S DiPaola,John R,John N,et al.Characterization of aNovel Prostate-Specific-Antigen?Activated Peptide-Doxo-rubicin Conjugate in Patients With Prostate Cancer[J].J ClinOnco,2002,20(7):1874-1879.
[8]Sounni N E.Membrane type-matrix metalloproteinases andtumor progression[J].Biochimie 2005,87:329?342.
[9]Ahmed MMansour,Joachim Drevs,Norbert Esser,et al.Anewapproach for the treatment of malignant melanoma:enhanced an-titumor efficacy of an albumin-binding doxorubicin prodrug thatis cleaved by matrix metalloproteinase 2[J].Can Res,2003,63:4062?4066.
[10]Toni Kline,Michael Y Torgov,Brian A Mendelsohn,et al.No-vel Antitumor Prodrugs Designed for Activation by MatrixMetallo-proteinases-2 and-9[J].Mole Pharma,2003,1(1):9-22.
[11]Charles F Albright,Nilsa Graciani,Wei Han,et al.Matrix met-alloproteinase?activated doxorubicin prodrugs inhibit HT1080xenograft growth better than doxorubicin with less toxicity[J].Mol Cancer Ther,2005,4(5):751-760.
[12]Chen WT,Kelly T.Seprase complexes in cellular invasiveness[J].Can Metas Rev,2003,22(2-3):259-269.
[13]Kelly T.Seprase,a membrane-bound protease,is overex-pressed by invasive ductal carcinoma cells of human breast canc-ers[J].Modern Pathology,1998,11(9):855-863.
[14]Mueller MM,Fusenig NE.Friends or foes—bipolar effects of thetumour stroma in cancer[J].Nat rev,2004,4:839-849.
[15]冯作化.医学分子生物学[M].北京:人民卫生出版社,2002.260-265.
【关闭】
